


GA201		3-((R)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea,
GA202		3-((S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea, and
GA203		3-(1-(4-(2-(benzyloxy)ethoxy)naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea.

19. ~~A method of preventing and/or treating a subject, comprising administering to said subject a therapeutically effective amount~~ Use of a compound of formula (I) according to any one of claims 1-18, or a pharmaceutically acceptable salt or adduct thereof, in the preparation of a medicament for treating ~~wherein the~~ a subject ~~has~~having a disease which is pathophysiologically mediated by the ghrelin receptor.

20. The ~~method~~ use of claim 19, wherein said disease is obesity, overweight, eating disorder, diabete, metabolic syndrome, cachexia resulting from cancer, congestive heart failure, wasting due to ageing or AIDS, chronic liver failure, chronic obstructive pulmonary disease, gastrointestinal disease, gastric disorder or substance abuse.

21. The ~~method~~ use of claim 20, wherein said metabolic disorder is selected from the group consisting of diabetes, Type I diabetes, Type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, obesity, aging, Syndrome X, atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease.

22. The ~~method~~ use of claim 20, wherein said gastric disorder is selected from the group consisting of Post-operative ileus (POI), diabetic gastroparesis, and opioid induced bowel dysfunction.

23. The ~~method~~ use of claim 20, wherein said gastrointestinal disease is selected from the group consisting of irritable bowel syndrome, gastritis, acid reflux disease, gastroparesis, and functional dyspepsia.

24. The ~~method~~ use of claim 20, wherein said substance abuse is alcohol or drug abuse.

25. The ~~method~~ use of claim 24, wherein said drug is selected from the group consisting of amphetamines, barbiturates, benzodiazepines, cocaine, methaqualone, and opioids.

26. The ~~method~~ use of any one of claims 19 to 25, wherein said compound or a pharmaceutically acceptable salt or adduct thereof, is a ghrelin receptor modulator.

27. The ~~method~~ use of any one of claims 19 to 26, wherein said compound or a pharmaceutically acceptable salt or adduct thereof, is a ghrelin receptor agonist.

28. The ~~method~~ use of any one of claims 19 to 27, wherein said compound or a pharmaceutically acceptable salt or adduct thereof, is a ghrelin receptor antagonist.

29. The ~~method~~ use of any one of claims 19 to 28, wherein said compound or a pharmaceutically acceptable salt or adduct thereof, is administered by one or more routes selected from the group consisting of rectal, buccal, sublingual, intravenous, subcutaneous, intradermal, transdermal, intraperitoneal, oral, eye drops, parenteral and topical administration.

30. The ~~method~~ use of any one of claims 19 to 29, wherein said administration is accomplished by administering an oral form of said compound or a pharmaceutically acceptable salt or adduct thereof.

31. The ~~method~~ use of any one of claims 19 to 30, wherein said compound or a pharmaceutically acceptable salt or adduct thereof, is administered in an amount of from about 0.01 microgram per Kg (μg/Kg) body weight per day to about 100 mg/Kg body weight per day, from about 0.1 μg /Kg/day to about 10 mg/Kg/day, from about 1 μg /Kg /day to about 5 mg/ Kg /day, from about 10 μg /Kg/day to about 5 mg/Kg/day, from about 100 μg /Kg/day to about 5 mg/Kg/day, or from about 500 μg /Kg/day to about 5 mg/Kg/day.

32. The ~~method~~ use of any one of claims 19 to 31, further comprising administering one or more therapeutic agents.

33. The ~~method~~ use of any one of claims 19 to 32, wherein the subject is a human.

34. The ~~method~~ use of any one of claims 19 to 33, wherein the subject has been identified as needing treatment for the disease or the administration.

35. A pharmaceutical composition for preventing and/or treating a subject comprising a therapeutically effective amount of a compound according to any one of claims 1-18, and one or more pharmaceutically acceptable excipients.